REGN stock forecast
Our latest prediction for Regeneron Pharmaceuticals, Inc.'s stock price was made on the Sept. 10, 2019 when the stock price was at 283.72$.
In the short term (2weeks), REGN's stock price should outperform the market by 0.46%. During that period the price should oscillate between -3.98% and +5.06%.
In the medium term (3months), REGN's stock price should outperform the market by 0.44%. During that period the price should oscillate between -9.52% and +13.27%.Get email alerts
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
At the moment the company generates 7237M USD in revenues.
On its last earning announcement, the company reported a profit of 18.01$ per share.
The book value per share is 66.51$
Three months stock forecastSept. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|